Company

HLS Therapeutics Inc.

Headquarters: Toronto, ON, Canada

Employees: 92

CEO: Mr. Gilbert Godin

TSX: HLS -2.60%

Market Cap

C$115.8 Million

CAD as of July 1, 2024

US$84.3 Million

Market Cap History

HLS Therapeutics Inc. market capitalization over time

Evolution of HLS Therapeutics Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of HLS Therapeutics Inc.

Detailed Description

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

HLS Therapeutics Inc. has the following listings and related stock indices.


Stock: TSX: HLS wb_incandescent

Stock: FSX: 74D wb_incandescent

Details

Headquarters:

10 Carlson Court

Suite 701

Toronto, ON M9W 6L2

Canada

Phone: 647-495-9000

Fax: 416-213-0045